权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Mechanisms of spontaneous and vaccine mediated hepatitis C virus control to direct rational development of a novel HCV vaccine

自发和疫苗介导的丙型肝炎病毒控制机制指导新型丙型肝炎疫苗的合理开发

基本信息

批准号：
10614973
负责人：
ANDREA L COX
金额：
$ 47.34万
依托单位：
JOHNS HOPKINS UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-05-01 至 2026-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10614973
关键词：
Acute Acute Hepatitis C Aliquot Animals Antibodies Antibody Response Antibody titer measurement Binding Biological Assay Biological Specimen Banks Blood Blood Component Removal Cells Clinical Code Collection Counseling Development Elderly Elements Enrollment Ensure Enzyme-Linked Immunosorbent Assay Experimental Models Funding Future Genotype Goals Grant Harm Reduction Hepatitis C Hepatitis C Acquisition Hepatitis C Antibodies Hepatitis C Incidence Hepatitis C Vaccine Hepatitis C virus Human Immune response Immunity Infection Infrastructure Injecting drug user Location Lymphocyte Macaca Measurement Measures Mediating Mediator Monitor Monoclonal Antibodies Mus Neutralization Tests Outcome Participant Peripheral Blood Mononuclear Cell Persons Pharmacotherapy Phase Phylogenetic Analysis Plasma Population Populations at Risk RNA Recovery Recurrence Research Research Personnel Resources Risk Sampling Scientist Serology test Serum Specimen Standardization Testing Time United States National Institutes of Health Vaccinated Vaccination Vaccines Viremia Virus Visit acute infection chronic infection clinical care clinically relevant cohort design efficacy trial env Gene Products experimental study high risk immunogenicity in vivo infection risk injection drug use nonhuman primate novel outreach prophylactic prospective recruit repository response screening seroconversion success treatment program vaccine candidate vaccine evaluation vaccine-induced antibodies

项目摘要

Scientific Core (Core B) Project Summary The Scientific Core is designed to successfully recruit and monitor HCV-antibody-negative people who inject drugs (PWID) for HCV infection and to identify and characterize acute infections and reinfections by testing sera for HCV RNA and seroconversion with serial ALT and HCV RNA testing. The infrastructure of Core B was necessary for completion of the first trial of an HCV vaccine in people at risk of HCV infection and will be useful in potential future trials of HCV vaccines. Plasma, serum, and peripheral blood mononuclear cells will be collected from prior to infection, during infection, and through the time when infection outcome (clearance or persistence of virus as well as during reinfection. Samples are stored in the repository for use in Projects 1-4, as well as for other HCV investigators. Core B will also provide standardized serological testing to quantitate HCV envelope-specific antibodies in plasma or serum of humans or vaccinated animals. Quantitative analyses of vaccine-induced plasma or serum antibody responses are essential to identify the most promising vaccine candidates. By applying a standardized set of assays to samples post-vaccination and from humans who successfully cleared multiple HCV infections, we will be able to make quantitative and qualitative comparisons between vaccine-induced antibody responses in mice or nonhuman primates (Projects 3 and 5) and human responses that are protective against HCV in vivo (Project 2). This will facilitate identification the vaccines most likely to be protective when advanced to human trials.

科学核心（核心B）项目总结